Conflicts of interest: The authors have declared no conflicts of interest.
Review article: probiotics in gastrointestinal and liver diseases
Article first published online: 7 DEC 2007
Alimentary Pharmacology & Therapeutics
Volume 26, Issue Supplement s2, pages 133–148, December 2007
How to Cite
JONKERS, D. and STOCKBRÜGGER, R. (2007), Review article: probiotics in gastrointestinal and liver diseases. Alimentary Pharmacology & Therapeutics, 26: 133–148. doi: 10.1111/j.1365-2036.2007.03480.x
This article appeared as part of a supplement sponsored by Nycomed bv.
- Issue published online: 7 DEC 2007
- Article first published online: 7 DEC 2007
- Publication data Accepted 26 August 2007
Background Probiotics, defined as live micro-organisms with beneficial effects for the host, are widely applied in gastrointestinal and liver diseases.
Aim and method To review the available evidence of clinical trials on probiotics in gastrointestinal and liver diseases, with a major focus on irritable bowel syndrome, inflammatory bowel disease, pancreatitis and chronic liver diseases.
Results Evidence for the therapeutic or preventive application of particular probiotic strains is available for antibiotic-associated diarrhoea, rota-virus-associated diarrhoea and pouchitis. Results are encouraging for irritable bowel syndrome, ulcerative colitis and for reducing side effects by Helicobacter pylori eradication therapies, but are less clear for Crohn’s disease, lactose intolerance and constipation. In general, for most of these patient groups, more placebo-controlled methodologically well-designed studies that pay attention to both clinical outcome and mechanistic aspects are required. The application in liver disease and pancreatitis is promising, but more human trials have to be awaited. Possible mechanisms of probiotics include modulation of the intestinal microbiota and the immune system, but different bacterial may have different effects.
Conclusion Further insight into disease entities and the functioning of probiotic strains is required to be able to select disease-specific strains, which have to be tested in well-designed placebo-controlled studies.